Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (CANCELLED) .

20. (CURRENTLY AMENDED) A method of respiratory therapy comprising the steps of:

providing a pressure-assisted breathing system having a pressure-generating circuit and a respiratory circuit adapted to be coupled to a patient interface device, wherein the pressure-generating circuit contains a first gas flow of sufficiently high-volume to maintain positive pressure in the system and wherein the respiratory circuit contains a second gas flow of lower volume than the first gas flow;

engaging the patient interface device with the patient's respiratory system; and introducing an aerosolized <u>liquid</u> medicament into the second gas flow by a vibrating aperture nebulizer coupled to the respiratory circuit, wherein the nebulizer is positioned and configured to avoid dilution of the aerosolized <u>liquid</u> medicament that is delivered to the patient's respiratory system.

- 21. (CANCELLED)
- 22. (CURRENTLY AMENDED) A method according to claim 20 wherein the nebulizer comprises a <u>liquid</u> reservoir having a capacity equal to one unit dose of <u>liquid</u> medicament and substantially all of the contents of the reservoir is delivered to the patient's respiratory system.
- 23. (ORIGINAL) A method according to claim 22 wherein the dose is 4 ml or less of medicament.
- 24. (PREVIOUSLY PRESENTED) A method of delivering a surfactant to a patient's respiratory system which comprises the steps of:

providing a CPAP system having a pressure-generating circuit with a first gas flow of sufficiently high volume to maintain continuous positive airway pressure in the system, a respiratory circuit connecting the pressure-generating circuit to a patient interface device, wherein the respiratory circuit contains a second gas flow of lower volume than said first gas flow, and a vibrating aperture nebulizer coupled to the respiratory circuit at a distance from the patient interface device sufficient to provide an acceptable efficiency of delivering a liquid surfactant to the patient's respiratory system;

introducing the liquid surfactant into the nebulizer;
aerosolizing the surfactant in the nebulizer; and
entraining the aerosolized surfactant into the second gas flow of the respiratory
circuit to avoid dilution of the aerosolized surfactant delivered to the patient.

- 25. (ORIGINAL) The method of claim 24 wherein the surfactant is a phospholipid.
- 26. (PREVIOUSLY PRESENTED) The method of claim 24 wherein 6-18% of the aerosolized surfactant introduced into the system is delivered to the patient.
- 27. (PREVIOUSLY PRESENTED) The method of claim 24 wherein the nebulizer comprises a reservoir having a capacity substantially equal one unit dose of surfactant and substantially all of the contents of the reservoir is delivered to the patient.
- 28. (ORIGINAL) The method of claim 24 wherein the dose is equal to 10 mg or less of surfactant.
- 29. (PREVIOUSLY PRESENTED) The method of claim 24 wherein the patient interface device is selected from the group consisting of nasal prongs, an oral/nasal mask, a nasal mask, nasopharyngeal prongs, a nasopharyngeal tube, a tracheotomy tube, an endotracheal tube and a mouthpiece.
- 30. (PREVIOUSLY PRESENTED) The method of claim 29 wherein the patient interface device is an endotracheal tube.

31. (PREVIOUSLY PRESENTED) The method of claim 22 wherein a volume of medicament delivered is sufficient for one treatment.